Glycaemic control and hypoglycaemia in metformin-treated T2DM patients with exenatide BID vs insulin lispro TID added to titrated insulin glargine QD: the 4B trial

被引：0
|
作者：
Wolffenbuttel, B. H. R. [1 ]
Nauck, M. A. [2 ]
Shaginian, R.
Malone, J. [3 ]
Cleall, S. [4 ]
de Vries, D.
Hoogwerf, B.
MacConell, L. [5 ]
Diamant, M. [6 ]
机构：
[1] Univ Groningen, NL-9700 AB Groningen, Netherlands
[2] Diabet Zentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Eli Lilly & Co, Windlesham, Surrey, England
[5] Bristol Myers Squibb Co, San Diego, CA USA
[6] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
来源：
DIABETOLOGIA | 2013年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 41 条
  • [31] Once-Weekly Exenatide Used for 6 Months Provided Both Improved Glycemic Control and Weight Loss Compared to Sitagliptin, Pioglitazone, or Insulin Glargine in Metformin-Treated Patients with Type 2 Diabetes
    Horton, Edward
    Taylor, Kristin
    Porter, T. K. Booker
    Han, Jenny
    Wilhelm, Ken
    Harris, Carmen
    [J]. DIABETES, 2010, 59 : A163 - A163
  • [32] Predictors of good glycaemic control in Chinese T2DM patients treated with biphasic insulin aspart 30:Data from the A1chieve study
    石勇铨
    [J]. China Medical Abstracts (Internal Medicine), 2017, 34 (02) : 92 - 93
  • [33] The DURABLE trial 24-week results: Safety and efficacy of insulin lispro mix 25 vs. insulin glargine added to oral antihyperglycaemic agents (OHAs) in patients with type 2 diabetes (T2D)
    Wolffenbuttel, B. H. R.
    Buse, J.
    Herman, W. H.
    Jiang, H.
    Fahrbach, J.
    Palaisa, M.
    Martin, S.
    [J]. DIABETOLOGIA, 2008, 51 : S386 - S386
  • [34] Once-Weekly GLP-1 Receptor Agonist Albiglutide vs. Titrated Prandial Lispro Added on to Titrated Basal Insulin Glargine in Type 2 Diabetes (T2D) Uncontrolled on Glargine Plus Oral Agents: Similar Glycemic Control With Weight Loss and Less Hypoglycemia
    Rosenstock, Julio
    Ahren, Bo
    Chow, Francis
    Fonseca, Vivian
    Gross, Jorge
    Ratner, Robert
    Johnson, Susan
    Stewart, Murray
    Yang, Fred
    Leiter, Lawrence
    [J]. DIABETES, 2012, 61 : A15 - A16
  • [35] iGlarLixi Fixed-Ratio Combination vs. Insulin Glargine and Lixisenatide in Patients with T2DM Treated Previously with Two Oral Antidiabetics: LixiLan-O Subgroup Analysis
    Russell-Jones, David
    Mccrimmon, Rory J.
    Barber, Thomas M.
    Baradez, Cecile
    Baxter, Michael A.
    Davies, Melanie
    [J]. DIABETES, 2017, 66 : LB35 - LB35
  • [36] Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA): a study to determine the effect of a structured SMBG intervention
    Scavini, Marina
    Bosi, Emanuele
    Ceriello, Antonio
    Giorgino, Francesco
    Porta, Massimo
    Tiengo, Antonio
    Vespasiani, Giacomo
    Bottalico, Davide
    Marino, Raffaele
    Parkin, Christopher
    Bonizzoni, Erminio
    Cucinotta, Domenico
    [J]. ACTA DIABETOLOGICA, 2013, 50 (05) : 663 - 672
  • [37] Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA): a study to determine the effect of a structured SMBG intervention
    Marina Scavini
    Emanuele Bosi
    Antonio Ceriello
    Francesco Giorgino
    Massimo Porta
    Antonio Tiengo
    Giacomo Vespasiani
    Davide Bottalico
    Raffaele Marino
    Christopher Parkin
    Erminio Bonizzoni
    Domenico Cucinotta
    [J]. Acta Diabetologica, 2013, 50 : 663 - 672
  • [38] Impact of active vs usual algorithmic insulin titration and point-of-care (POC) vs laboratory measurement of A1C on glycemic control in patients initiating insulin glargine (GLAR) for type 2 diabetes (T2DM): The GOAL A1C study
    Kennedy, L
    Herman, WH
    Harris, A
    Strange, P
    [J]. DIABETES, 2005, 54 : A133 - A133
  • [39] Similar glycemic control is achieved after discontinuation of thiazolidinediones (TZDs) and metformin (MET) in patients initiating insulin glargine (GLAR) as add-on therapy for type 2 Diabetes (T2DM): The GOAL A1C study
    Herman, WH
    Kennedy, L
    Harris, A
    Strange, P
    [J]. DIABETES, 2005, 54 : A140 - A140
  • [40] A Multi-Center, Open, Randomized, Parallel-Group, 2 Arm Study to Compare the Efficacy and Safety of Insulin Add-On to Glimepiride/Metformin 1/500mg b.i.d vs. to Glimepiride 4mg qd in Type 2 DM Patients With Inadequate Glycemic Control
    Lee, Jae Min
    Park, Kang Seo
    Park, Soon Hyun
    Lim, Dong Mee
    Lee, Jong Min
    Park, Keun Yong
    Kim, Sang Jin
    [J]. DIABETES, 2012, 61 : A280 - A281
12345